These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Etoposide-induced hypersensitivity reactions. Report of two cases. Tucci E; Pirtoli L Chemioterapia; 1985 Dec; 4(6):460-2. PubMed ID: 3830414 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. Collier K; Schink C; Young AM; How K; Seckl M; Savage P J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441 [TBL] [Abstract][Full Text] [Related]
4. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Hayes FA; Abromowitch M; Green AA Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970 [TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. de Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M Am J Clin Oncol; 1994 Oct; 17(5):387-9. PubMed ID: 8092107 [TBL] [Abstract][Full Text] [Related]
6. [Etoposide in the treatment of recurrent malignant lymphoma]. Háber J; Klener P Vnitr Lek; 1986 Apr; 32(4):379-85. PubMed ID: 3727425 [No Abstract] [Full Text] [Related]
7. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia. Kellie SJ; Crist WM; Pui CH; Crone ME; Fairclough DL; Rodman JH; Rivera GK Cancer; 1991 Feb; 67(4):1070-5. PubMed ID: 1991254 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract. Kelsen DP; Magill GB; Cheng E; Dukeman M; Sordillo P; Heelan R; Yagoda A Cancer Treat Rep; 1983 May; 67(5):509-10. PubMed ID: 6850667 [No Abstract] [Full Text] [Related]
9. Phase II study of etoposide in the treatment of esophageal carcinoma. Coonley CJ; Bains M; Heelan R; Dukeman M; Kelsen DP Cancer Treat Rep; 1983 Apr; 67(4):397-8. PubMed ID: 6850656 [No Abstract] [Full Text] [Related]
10. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569 [TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity reactions to etoposide phosphate. Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Slayton RE; Blessing JA; Delgado G Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059 [No Abstract] [Full Text] [Related]
13. Etoposide--an effective single drug for treating bronchogenic carcinoma. Anderson G; Peel ET; Cheong CM; Broderick NJ Clin Oncol; 1982; 8(3):215-8. PubMed ID: 7140048 [No Abstract] [Full Text] [Related]
14. Hypersensitivity reactions to etoposide. Hoetelmans RM; Schornagel JH; ten Bokkel Huinink WW; Beijnen JH Ann Pharmacother; 1996 Apr; 30(4):367-71. PubMed ID: 8729891 [TBL] [Abstract][Full Text] [Related]
15. Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor. Mutafoğlu-Uysal K; Sarialioğlu F; Olgun N Turk J Pediatr; 2001; 43(2):172-4. PubMed ID: 11432501 [TBL] [Abstract][Full Text] [Related]